[CAS NO. 520-85-4] Medroxyprogesterone

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [520-85-4]

Catalog

HY-B0648

Brand

MCE

CAS

520-85-4

DESCRIPTION [520-85-4]

Overview

MDL	-
Molecular Weight	344.49
Molecular Formula	C22H32O3
SMILES	C[C@@]1([C@@]2(O)C(C)=O)[C@](CC2)([H])[C@@](C[C@H](C)C3=CC4=O)([H])[C@]([C@]3(CC4)C)([H])CC1

For research use only. We do not sell to patients.

7 Publications Citing Use of MCE

Summary

Medroxyprogesterone is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist. Target: Progesterone Receptor Medroxyprogesterone (MP), is a steroidal progestin drug which was never marketed for use in humans. An acylated derivative, medroxyprogesterone acetate (MPA), is clinically used as a pharmaceutical medicine. Compared to MPA, MP is over two orders of magnitude less potent as a progestogen. As such, MP itself is not used clinically, though it has seen limited use in veterinary medicine under the trade name Controlestril in France. In addition, it is an metabolite of MPA [1].

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00004650	National Institute of Dental and Craniofacial Research (NIDCR)\|Washington University School of Medicine\|Office of Rare Diseases (ORD)	Osteoporosis	August 1993	Phase 3
NCT00577122	Indiana University\|Translational Breast Cancer Research Consortium	Estrogen Receptor-negative Breast Cancer\|Progesterone Receptor-negative Breast Cancer\|Recurrent Breast Cancer\|Stage IV Breast Cancer	July 2007	Phase 2
NCT00000466	National Heart, Lung, and Blood Institute (NHLBI)\|National Institute on Aging (NIA)\|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)\|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Bone Diseases\|Cardiovascular Diseases\|Coronary Disease\|Diabetes Mellitus\|Heart Diseases\|Hypercholesterolemia\|Hypertension\|Myocardial Ischemia\|Osteoporosis\|Thrombosis\|Postmenopause	September 1987	Phase 3
NCT00033358	National Cancer Institute (NCI)	Endometrial Cancer	February 2002	Phase 2
NCT00016601	National Institute of Allergy and Infectious Diseases (NIAID)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	HIV Infections	June 2001	Not Applicable
NCT01143207	FHI 360\|Eastern Virginia Medical School	Contraception	May 2010	Not Applicable
NCT00044837	National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections		Phase 1
NCT05247268	Fudan University\|Peking Union Medical College Hospital	Endometrial Neoplasm Malignant Stage I	March 11, 2022	Phase 2
NCT00319566	University of California, San Francisco\|Wyeth is now a wholly owned subsidiary of Pfizer	Coronary Heart Disease	July 1992	Phase 3
NCT01776203	Kaiser Permanente	Dysfunctional Uterine Bleeding	January 2012	Phase 4
NCT02228681	Gynecologic Oncology Group\|Novartis Pharmaceuticals\|GOG Foundation	Advanced, Persistent, or Recurrent Endometrial Cancer	February 2015	Phase 2
NCT01148420	Women´s Health Care Clinic, Torrance, California	Dysfunctional Uterine Bleeding	January 2009	Phase 4
NCT00064025	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	Endometrial Adenocarcinoma\|Endometrial Adenosquamous Carcinoma\|Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation\|Recurrent Uterine Corpus Carcinoma\|Stage I Uterine Corpus Cancer\|Stage II Uterine Corpus Cancer\|Stage III Uterine Corpus Cancer\|Stage IV Uterine Corpus Cancer	April 2004	Phase 2
NCT02509767	Planned Parenthood Federation of America\|Pfizer\|Tara Health Foundation	Contraception	August 2015	Phase 4
NCT03018249	National Cancer Institute (NCI)\|NRG Oncology	FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma\|FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma\|FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma	October 11, 2017	Early Phase 1
NCT00066157	University of Wisconsin, Madison\|National Institute on Aging (NIA)	Alzheimer Disease	September 2001	Phase 2\|Phase 3
NCT01791413	Mahidol University	Endometriosis	March 2012	Phase 1\|Phase 2
NCT00360490	Bayer	Menorrhagia	July 2006	Phase 3
NCT00291369	Centre Leon Berard\|French Immunotherapy Intergroup\|SCAPP (Sub-Cutaneous Administration Proleukin Program)	Metastatic Renal Cell Carcinoma	December 1999	Phase 3
NCT00437658	AbbVie	Endometriosis	December 11, 2006	Phase 2
NCT01822288	Far Eastern Memorial Hospital	Menopausal Syndromes	November 16, 2012	Phase 4
NCT05565573	Hua Li\|Beijing Chao Yang Hospital	Fertility Sparing	November 1, 2022	Phase 2\|Phase 3
NCT00083824	Tufts University\|National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Heart Diseases\|Coronary Arteriosclerosis	March 2004	Phase 2\|Phase 3
NCT00169299	Kaiser Permanente\|National Institute on Aging (NIA)\|National Center for Complementary and Integrative Health (NCCIH)	Vasomotor Symptoms Associated With Menopause	June 2001	Phase 4
NCT02579590	Assiut University	Female Sexual Function	May 1, 2017
NCT04710017	Assiut University	Uterine Bleeding	February 1, 2021	Not Applicable
NCT00420342	Bayer	Postmenopause\|Hypertension\|Pre-Hypertension	January 2007	Phase 2
NCT00828542	University of Sao Paulo	Breastfeeding\|Contraception	July 2007	Not Applicable
NCT02894151	Chulalongkorn University	Clinically Diagnosed Endometriotic Patient Was Defined as a Woman Who Has Pelvic Pain and at Least One Evidence of PV or TVS	April 2015	Phase 2
NCT01019369	Carolyn L. Westhoff\|Family Planning Fellowship\|Pfizer\|Columbia University	Contraception	March 2010	Not Applicable
NCT00997893	University of Illinois at Chicago\|National Institute of Mental Health (NIMH)	Menopause\|Hot Flashes	December 2009	Phase 2
NCT03660046	Emory University\|National Institutes of Health (NIH)\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Hormonal Contraception	December 7, 2018
NCT03097120	Wake Forest University Health Sciences\|National Heart, Lung, and Blood Institute (NHLBI)	Heart Disease	January 1995	Phase 3
NCT03675139	Xiaojun Chen\|Fudan University	Endometrial Hyperplasia Without Atypia	February 26, 2019	Phase 2\|Phase 3
NCT01472315	Turku University Hospital	Sleep Apnea	January 2000	Phase 2\|Phase 3
NCT01463202	Beatrice Chen\|Society of Family Planning\|University of Pittsburgh	Contraception\|Postpartum Depression\|Lactation	November 2011	Phase 4
NCT01011751	Takeda	Adenocarcinoma, Prostate	April 2004	Phase 3
NCT00830414	Teva Pharmaceuticals USA	Healthy	April 2002	Phase 1
NCT01074892	University Hospital of North Norway\|Helse Nord\|Norwegian Cancer Society	Endometrial Hyperplasia	May 2005	Phase 4
NCT01056042	Prince of Songkla University	Endometriosis	June 2007	Phase 4
NCT00332553	Eli Lilly and Company	Vasomotor Symptoms\|Endometrial Safety	February 2002	Phase 2
NCT00000559	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Disease\|Heart Diseases\|Myocardial Ischemia\|Postmenopause	March 1995	Phase 3
NCT02103764	Mahidol University	Dysfunctional Uterine Bleeding	August 2013	Phase 3
NCT00743574	Yale University\|National Center for Research Resources (NCRR)	Polycystic Ovarian Syndrome\|Vitamin D Deficiency	August 2008	Not Applicable
NCT03309176	Radboud University Medical Center	Ovulation Disorder	June 21, 2016	Phase 4
NCT04669678	University of Washington\|Merck Sharp & Dohme LLC\|Wits Reproductive Health and HIV Institute	HIV Infections\|Contraception\|Drug-drug Interaction	November 17, 2021
NCT00416429	Centre Leon Berard	Kidney Cancer		Phase 3
NCT04910711	Botswana Harvard AIDS Institute Partnership\|University of Liverpool	Human Immunodeficiency Virus\|Contraception\|ART	October 21, 2021	Phase 4
NCT05491343	HaEmek Medical Center, Israel	Arteriovenous Malformations	August 2022	Phase 4
NCT01461824	Nationwide Children´s Hospital\|Society of Family Planning	Weight Gain\|Disorder of Bone Density and Structure, Unspecified\|Uterine Bleeding	September 2011	Phase 3
NCT00191113	Eli Lilly and Company	Turner Syndrome	February 1989	Phase 3
NCT02272647	Mayo Clinic	Healthy	December 2014	Phase 1
NCT00006133	National Center for Research Resources (NCRR)\|University of Alabama at Birmingham	Systemic Lupus Erythematosus	June 2000	Not Applicable
NCT05255653	Leiden University Medical Center\|Institute Gustave Roussy (sponsor p53abn-RED trial)\|Leiden University Medical center (sponsor MMRd-GREEN trial)\|University College London (sponsor NSMP-ORANGE trial)\|Canadian Clinical Trials Group (sponsor POLEmut-BLUE trial)\|Dutch Gynaecological Oncology Group\|Comprehensive Cancer Centre The Netherlands\|Cancer Research UK & UCL Cancer Trials Centre\|Dutch Cancer Society\|AstraZeneca	Endometrial Cancer	November 11, 2021	Phase 2\|Phase 3
NCT02357368	Lisa Haddad\|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|Emory University	HIV\|Contraception	February 2015	Phase 4
NCT02412436	AIDS Clinical Trials Group\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV-1 Infection\|Tuberculosis	November 3, 2015	Phase 2
NCT00030914	Alliance for Clinical Trials in Oncology\|National Cancer Institute (NCI)	Hot Flashes	April 2002	Phase 3
NCT02872818	Kayseri Education and Research Hospital	Apoptotic Signal Pathways in Endometrial Hyperplasia	October 2014	Phase 4
NCT04654741	Casa di Cura Privata Villa Mafalda	IVF\|Infertility	September 1, 2020	Phase 4
NCT00739830	Merck Sharp & Dohme LLC	Endometrial Cancer	August 2008	Phase 2
NCT00002920	Southwest Oncology Group\|National Cancer Institute (NCI)\|Cancer and Leukemia Group B	Breast Cancer\|Endometrial Cancer	March 1997	Phase 3
NCT00026286	Eastern Cooperative Oncology Group\|National Cancer Institute (NCI)	Breast Cancer\|Hot Flashes\|Menopausal Symptoms	September 2000	Phase 3
NCT04997811	Prof. Janet Dunn\|Blood Cancer UK\|Dudley Group NHS Foundation Trust\|University of Birmingham\|University of Manchester\|King´s College Hospital NHS Trust\|University of Warwick	Myelodysplastic Syndromes (MDS)	December 21, 2021	Phase 2
NCT02943655	Assiut University	Improve Quality of Life\|Heavy Menstrual Bleeding	November 1, 2017	Phase 3
NCT00006324	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV Infections	December 1999	Not Applicable
NCT02340013	Samuel Lunenfeld Research Institute, Mount Sinai Hospital\|University of Toronto	Infertility	July 2013	Phase 4
NCT00091728	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Chlamydia Infection\|Neisseriaceae Infection	September 1997
NCT02335203	Women and Infants Hospital of Rhode Island	Grade 1 Endometrial Endometrioid Adenocarcinoma\|Grade 2 Endometrial Endometrioid Adenocarcinoma\|Complex Atypical Endometrial Hyperplasia	February 2015	Phase 2
NCT00000605	National Heart, Lung, and Blood Institute (NHLBI)	Cardiovascular Diseases\|Coronary Arteriosclerosis\|Coronary Disease\|Heart Diseases\|Myocardial Ischemia\|Postmenopause	August 1996	Phase 3
NCT01191203	Emory University\|University of North Carolina\|National Institute of Allergy and Infectious Diseases (NIAID)	HIV	July 2010	Not Applicable
NCT00003179	Gynecologic Oncology Group\|National Cancer Institute (NCI)\|GOG Foundation	Endometrial Cancer	November 1998	Phase 2
NCT02122198	University of Colorado, Denver	Cognitive Impairment\|Executive Dysfunction\|Endothelial Dysfunction\|Cardiovascular Disease	September 8, 2014	Not Applicable
NCT00808132	Pfizer	Menopause\|Osteoporosis	January 2009	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 145.14 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9028 mL	14.5142 mL	29.0284 mL
5 mM	0.5806 mL	2.9028 mL	5.8057 mL
10 mM	0.2903 mL	1.4514 mL	2.9028 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (7.26 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] http://en.wikipedia.org/wiki/Medroxyprogesterone

Synonyms

Pregn-4-ene-3,20-dione, 17-hydroxy-6-methyl-, (6α)-

Pregn-4-ene-3,20-dione, 17-hydroxy-6α-methyl-

Progesterone, 17-hydroxy-6α-methyl-

(6α)-17-Hydroxy-6-methylpregn-4-ene-3,20-dione

17-Hydroxy-6α-methylpregn-4-ene-3,20-dione

17α-Hydroxy-6α-methylprogesterone

Medroxyprogesteron

Medroxyprogesterone

6α-Methyl-17α-hydroxyprogesterone

U 8840

6α-Methyl-4-pregnen-17α-ol-3,20-dione

17-Hydroxy-6α-methylprogesterone

6α-Methyl-17-hydroxyprogesterone

6α-Methyl-17α-hydroxypregn-4-ene-3,20-dione

NSC 27408

6α-Methyl-17R-hydroxyprogesterone

Medoxyprogesterone